肺癌患者的胚系基因变异研究
BACKGROUND: Germline alterations and smoking status in lung cancer could inform etiology and clinical decisions. We investigated the prevalence of germline alterations in predisposition genes across various lung cancer histologies in two large populations.…
要点
- 吸烟者与不吸烟者的致病/可能致病胚系变异比例相似。
- 常见胚系变异基因包括MUTYH、ATM、BRCA2和EGFR。
- 不吸烟者EGFR突变型肿瘤中胚系EGFR变异比例高于野生型。
核心结论
- 不同人群肺癌亚型中致病/可能致病胚系变异的分布相似,提示增加二代胚系测序可能改善风险评估。
研究设计与样本
- 在英国生物银行1330例肺癌患者中按吸烟状态分析46个基因的致病/可能致病变异。
主要发现
- Tempus测序显示吸烟者致病/可能致病变异比例为4.8%,不吸烟者为5.8%。
- 常见变异基因包括MUTYH(吸烟者1.3% vs 不吸烟者1.1%)、ATM(0.7% vs 1.0%)、BRCA2(0.6% vs 0.9%)和EGFR(<0.1% vs 0.4%)。
- 不吸烟者中EGFR突变型(n=549)与野生型(n=1025)肿瘤的胚系变异:MUTYH(1.1% vs 1.1%)、ATM(0.7% vs 1.1%)、EGFR(1.1% vs 0%)。
- 非小细胞肺癌与小细胞肺癌的胚系变异:MUTYH(1.3% vs 0.3%)、ATM(0.8% vs 0.3%)、BRCA2(0.7% vs 0%)。
- 英国生物银行中吸烟者致病/可能致病变异比例为4.3%,不吸烟者为5.1%,主要涉及ATM(0.8%)、BRCA2(0.79%)、MUTYH(0.62%)和CHEK2(1.01%)。
临床怎么用
- 对肺癌患者进行胚系基因检测可能有助于识别遗传风险,尤其在不吸烟者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Germline alterations and smoking status in lung cancer could inform etiology and clinical decisions. We investigated the prevalence of germline alterations in predisposition genes across various lung cancer histologies in two large populations. PATIENTS AND METHODS: Germline sequencing of 11 740 primary lung cancers was carried out with Tempus xT tumor-normal matched assay (DNA sequencing of 648 genes at an average coverage of 500×, normal specimens at 150× coverage, full transcriptome RNA sequencing). Pathogenic/likely pathogenic (P/LP) potential germline alterations in 46 genes were compared between smokers and never smokers; never smokers somatic EGFR altered (sEGFRalt) and wild type (sEGFRwt); non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) histologies; and NSCLC sEGFRalt and NSCLC sEGFRwt. P/LP variants were investigated in these 46 genes in 1330 patients with lung cancer from the UK Biobank by smoking status. RESULTS: Tempus sequencing revealed P/LP alterations in 4.8% of smokers and 5.8% of never smokers, with most alterations in MUTYH (1.3% versus 1.1%), ATM (0.7% versus 1.0%), BRCA2 (0.6% versus 0.9%), and EGFR (<0.1% versus 0.4%). Never smoker sEGFRalt (n = 549) and sEGFRwt (n = 1025) tumors had alterations in MUTYH (1.1% versus 1.1%), ATM (0.7% versus 1.1%), and EGFR (1.1% versus 0%). NSCLC and SCLC tumors had alterations in MUTYH (1.3% versus 0.3%), ATM (0.8% versus 0.3%), and BRCA2 (0.7% versus 0%). sEGFRalt and sEGFRwt NSCLC tumors had germline alterations in MUTYH (1.6% versus 1.3%), ATM (0.5% versus 0.8%), EGFR (1.3% versus 0%), and BRCA2 (0.8% versus 0.6%). UK Biobank patients had similar P/LP alterations: 4.3% of smokers and 5.1% of never smokers, with most germline alterations in ATM (0.8%), BRCA2 (0.79%), and MUTYH (0.62%) in smokers and MUTYH (1.5%) and CHEK2 (1.01%) in never smokers. CONCLUSION: Similar distribution of P/LP potential germline alterations in lung cancer subtypes from distinct populations by smoking status suggests that increased next-generation germline sequencing may improve risk assessment.
引用
- Govindan R, Navo K, Huang M, et al. Germline alterations in patients with lung cancer. Ann Oncol. 2025. PMID: 41412497. doi:10.1016/j.annonc.2025.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。